Aspartic Protease Inhibitors, Compositions, and Associated Therapeutic Methods
Posted Feb 27 2011 7:00pm
Description of Invention: The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Drug-resistance is a critical factor contributing to the gradual loss of clinical benefit to treatments for HIV infection. Accordingly, combination therapies have further evolved to address the mutating resistance of HIV. However, there has been great concern regarding the apparent growing resistance of HIV strains to current therapies.
The subject invention provides compounds which may serve as therapeutic candidates for inhibition of HIV-1 PR (protease) and thus serve in controlling AIDS, as well as having anti-malarial properties. These compounds may be used in combination with other protease inhibitors or inhibitors of HIV-1 reverse transcriptase, especially in patients who have developed resistance to other HIV protease inhibitors. These inhibitors have high potency, lower molecular weight, and lower lipophilicity than previous compounds, as well as a better profile towards drug resistant mutant strains of HIV.
Inventors: Ramnarayan S Randad (NCI) John W Erickson (NCI) Michael A Eissenstat (NCI) Lucyna Lubkowska (NCI)
For Licensing Information Please Contact: Sally Hu Ph.D., M.B.A. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5606 Fax: 301-402-0220